An observational study in Envenomation, Snakebite and Envenomation, sponsored by Jubilee Mission Medical College and Research Institute. Completed at 1 site in India. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Jubilee Mission Medical College and Research Institute · Observational
Several controversies exist in Hypnale bite management in Kerala. Even though leading bodies like WHO recommend against using antivenom for hypnale bites, many physicians still administer antivenom for snakebites even when the culprit snake is identified. Anecdotal experience suggests that the reasons for doing so range from lack of confidence in the identification of the snake, confusion as to whether or not to approach it syndromically and symptomatically rather than relying on the species identification, doubts as to whether there exists para-specific neutralization capability for the available polyvalent antivenom and fear of medicolegal culpability in denying antivenom in a case of 'snake envenomation'. To date, these domains and rationale have not been studied. It is also to be kept in mind that the evidence behind the WHO recommendation against the use of antivenom in Hypnale is based on expert opinion and case reports. The investigators intend to compare clinical manifestation and outcome amongst Hypnale hypnale bite patients who received the polyvalent antivenom to those who did not.
The investigators also intend to describe the clinical and laboratorical profile of patients with Hypnale hypnale envenomation .
Hump-nosed pit viper bites are the second most common snakebite presented to our institute as evidenced by the data in our snakebite registers. Acute kidney injury is reported in nearly 10% of the cases in our institute.
Since 2016, the participating institute maintains a snakebite register that records the patient's name, hospital number, date and time of the bite, hospital admission, and snake identification data after expert confirmation, if done. The investigators intend to review the cases with confirmed Hypnale envenomation and describe the clinical and laboratory profile of patients and their course of hospitalization.
Hump-nosed pit viper envenomation, the venom components, and the pharmacodynamics of the venom are unique to the region that it has missed the attention of many experts in the field. The current available polyvalent antivenom does not utilize the venom of Hypnale. Yet, antivenom is used by physicians for snakebites even when the culprit snake is identified, citing many reasons. The reasons range from snake misidentification to doubts as to whether para-specific neutralization capability exists for the available polyvalent antivenom. Often fear of medicolegal culpability in denying antivenom in a case of 'snake envenomation', and confusion as to whether or not to approach it syndromically and symptomatically rather than relying on the species identification also comes into play.
38 studies on the registry are indexed under Snake Bites; 11 are open to participants now.
This study's enrollment of 41 is below the median of 99 across 19 observational studies indexed under Snake Bites.
Browse Snake Bites studies →Jubilee Mission Medical College and Research Institute is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Hypnale hypnale bite that were treated at a tertiary care centre in central Kerala, India during the period from April 2017 to December 2021.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Case records of all snakebite in which the specimen brought is identified as Hump-nosed pit viper (Hypnale hypnale)
Exclusion Criteria:
Patients With Hypnale Hypnale Bite receiving Antivenom for local or systemic signs of envenomation
Drug: Antivenom Snakes
Patients With Hypnale Hypnale Bite not receiving Antivenom for local or systemic signs of envenomation
No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
Also known as: The polyvalent f(ab')2 antibody
Mortality among patients administered antivenom compared to those who did not received the antivenom
Mortality among patients administered antivenom compared to those who did not received the antivenom for local or systemic signs of envenomation
Time frame: 3 months
Morbidity among patients administered antivenom compared to those who did not received the antivenom
Morbidity among patients administered antivenom compared to those who did not received the antivenom for local or systemic signs of envenomation
Time frame: 3 months
Clinical profile of patients with Hypnale hypnale envenomation
Clinical profile of patients with confirmed bite Hypnale hypnale with regards to local or systemic signs of envenomation
Time frame: 3 months
Laboratorical profile of patients with Hypnale hypnale envenomation
Laboratorical profile of patients with confirmed bite Hypnale hypnale with regards to local or systemic signs of envenomation
Time frame: 3 months
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jubilee Mission Medical College and Research Institute